Calidar Advances Breast Cancer Diagnostics with First-in-Human Study of 4D Mammography Technology
In an exciting development for breast cancer diagnostics, Calidar, Inc., an innovative startup specializing in precision diagnostic imaging, has successfully completed enrollment in its first-in-human study of the novel 4D Mammography system. This significant milestone was achieved in collaboration with Baptist Health Hardin, located in Elizabethtown, Kentucky. The clinical study enrolled a total of 61 patients and aims to evaluate the effectiveness of a next-generation imaging platform designed to improve the detection of breast cancer.
The 4D Mammography system represents a state-of-the-art innovation in diagnostic imaging, utilizing advanced X-ray diffraction technology to measure molecular-level signals in breast tissue. This capability distinguishes it from traditional mammography, which primarily focuses on detecting structural changes within the breast. With the enrollment phase now complete, Calidar and its clinical partners are set to analyze the collected data to assess the system's performance in differentiating between healthy and cancerous tissue.
Dr. Carpenter, the Chief Technology Officer at Calidar, expressed optimism about the initial results, stating, "First-in-human is the gate that separates promise from evidence. We cleared it — and the early performance data is directionally aligned with our clinical thesis, with early signals pointing to up to 4x improvement in precision over 3D mammography." Ongoing data analysis seeks to validate these findings further, marking a significant step forward in breast cancer diagnostics, which is especially critical in a landscape burdened by high rates of benign breast biopsies and inconclusive imaging results.
The landscape of breast cancer diagnostics is characterized by considerable clinical challenges. In the U.S. alone, approximately 1.8 million breast biopsies are performed annually, with a staggering 70-80% deemed benign. This not only contributes to over $7.4 billion in healthcare costs each year but also places added pressure on medical professionals, including radiologists and pathologists. Furthermore, unclear imaging results lead to delayed diagnoses for around 60,000 breast cancer patients each year. The innovative 4D Mammography system aims to change this troubling trend by offering a clearer diagnostic picture through detailed measurement of tissue structures and compositions — going beyond mere shape and density assessments.
Baptist Health Hardin, the clinical research site for the study, played a pivotal role in enrolling patients presenting with findings that warranted further investigation. Each participant underwent a 4D Mammogram aimed at testing the system's efficacy in distinguishing between healthy tissue and potential malignancies, with results benchmarked against traditional mammography devices. Importantly, the study was conducted under investigational use, meaning that the results will not inform immediate patient care.
Plans are already underway for a more extensive multi-site pivotal study as Calidar launches a Series A fundraising campaign aimed at supporting this next phase of development. Following the completion of this pivotal study, Calidar intends to pursue FDA approval for the 4D Mammography system. It is crucial to note that the 4D Mammography system is still under investigation and has not yet received clearance or approval from the U.S. Food and Drug Administration, nor is it available for commercial sale.
Calidar, Inc. stands at the forefront of medical technology innovation, with a mission to harness the capabilities of volumetric X-ray diffraction imaging to transform breast cancer diagnostics. Their 4D Mammography system is designed to significantly enhance diagnostic accuracy and reduce unnecessary biopsies, ensuring that breast cancer can be detected earlier and more reliably.
Baptist Health Hardin provides essential healthcare services to roughly 400,000 residents across ten counties in central Kentucky, operating 300 acute care beds and maintaining a robust network of nearly 500 physicians across various specialties. Holding the Pathway to Excellence designation from the American Nurses Credentialing Center (ANCC), Baptist Health Hardin is committed to delivering high-quality care to its community, further amplifying the significance of this clinical study in their contributions to healthcare.
As the study progresses, insights gained from the enrollment and results will provide invaluable data for the future of breast cancer diagnostics, heralding a new era of precision medicine in the fight against this pervasive disease.
The 4D Mammography system represents a state-of-the-art innovation in diagnostic imaging, utilizing advanced X-ray diffraction technology to measure molecular-level signals in breast tissue. This capability distinguishes it from traditional mammography, which primarily focuses on detecting structural changes within the breast. With the enrollment phase now complete, Calidar and its clinical partners are set to analyze the collected data to assess the system's performance in differentiating between healthy and cancerous tissue.
Dr. Carpenter, the Chief Technology Officer at Calidar, expressed optimism about the initial results, stating, "First-in-human is the gate that separates promise from evidence. We cleared it — and the early performance data is directionally aligned with our clinical thesis, with early signals pointing to up to 4x improvement in precision over 3D mammography." Ongoing data analysis seeks to validate these findings further, marking a significant step forward in breast cancer diagnostics, which is especially critical in a landscape burdened by high rates of benign breast biopsies and inconclusive imaging results.
The landscape of breast cancer diagnostics is characterized by considerable clinical challenges. In the U.S. alone, approximately 1.8 million breast biopsies are performed annually, with a staggering 70-80% deemed benign. This not only contributes to over $7.4 billion in healthcare costs each year but also places added pressure on medical professionals, including radiologists and pathologists. Furthermore, unclear imaging results lead to delayed diagnoses for around 60,000 breast cancer patients each year. The innovative 4D Mammography system aims to change this troubling trend by offering a clearer diagnostic picture through detailed measurement of tissue structures and compositions — going beyond mere shape and density assessments.
Baptist Health Hardin, the clinical research site for the study, played a pivotal role in enrolling patients presenting with findings that warranted further investigation. Each participant underwent a 4D Mammogram aimed at testing the system's efficacy in distinguishing between healthy tissue and potential malignancies, with results benchmarked against traditional mammography devices. Importantly, the study was conducted under investigational use, meaning that the results will not inform immediate patient care.
Plans are already underway for a more extensive multi-site pivotal study as Calidar launches a Series A fundraising campaign aimed at supporting this next phase of development. Following the completion of this pivotal study, Calidar intends to pursue FDA approval for the 4D Mammography system. It is crucial to note that the 4D Mammography system is still under investigation and has not yet received clearance or approval from the U.S. Food and Drug Administration, nor is it available for commercial sale.
Calidar, Inc. stands at the forefront of medical technology innovation, with a mission to harness the capabilities of volumetric X-ray diffraction imaging to transform breast cancer diagnostics. Their 4D Mammography system is designed to significantly enhance diagnostic accuracy and reduce unnecessary biopsies, ensuring that breast cancer can be detected earlier and more reliably.
Baptist Health Hardin provides essential healthcare services to roughly 400,000 residents across ten counties in central Kentucky, operating 300 acute care beds and maintaining a robust network of nearly 500 physicians across various specialties. Holding the Pathway to Excellence designation from the American Nurses Credentialing Center (ANCC), Baptist Health Hardin is committed to delivering high-quality care to its community, further amplifying the significance of this clinical study in their contributions to healthcare.
As the study progresses, insights gained from the enrollment and results will provide invaluable data for the future of breast cancer diagnostics, heralding a new era of precision medicine in the fight against this pervasive disease.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.